Instituto de Investigación Biomédica de A Coruña (INIBIC)
Research center
Pablo
García Pavía
Publications by the researcher in collaboration with Pablo García Pavía (89)
2024
-
Aficamten for Symptomatic Obstructive Hypertrophic Cardiomyopathy
The New England journal of medicine, Vol. 390, Núm. 20, pp. 1849-1861
-
Biallelic Loss of Function Variants in Myocardial Zonula Adherens Protein Gene (MYZAP) Cause a Severe Recessive Form of Dilated Cardiomyopathy
Circulation: Heart Failure
-
Clinical Features and Outcomes of Pediatric MYH7-Related Dilated Cardiomyopathy
Journal of the American Heart Association, Vol. 13, Núm. 21, pp. e036208
-
Dosing and Safety Profile of Aficamten in Symptomatic Obstructive Hypertrophic Cardiomyopathy: Results From SEQUOIA-HCM
Journal of the American Heart Association, Vol. 13, Núm. 15, pp. e035993
-
Efficacy and Safety of Aficamten in Symptomatic Nonobstructive Hypertrophic Cardiomyopathy: Results From the REDWOOD-HCM Trial, Cohort 4
Journal of Cardiac Failure
-
Impact of Aficamten on Disease and Symptom Burden in Obstructive Hypertrophic Cardiomyopathy: Results From SEQUOIA-HCM
Journal of the American College of Cardiology, Vol. 84, Núm. 19, pp. 1821-1831
-
Intermediate-effect size p.Arg637Gln in FHOD3 increases risk of HCM and is associated with an aggressive phenotype in homozygous carriers
Journal of Medical Genetics, Vol. 61, Núm. 5, pp. 423-427
-
Penetrance of Dilated Cardiomyopathy in Genotype-Positive Relatives
Journal of the American College of Cardiology, Vol. 83, Núm. 17, pp. 1640-1651
-
Phenotype and Clinical Outcomes in Desmin-Related Arrhythmogenic Cardiomyopathy
JACC: Clinical Electrophysiology, Vol. 10, Núm. 6, pp. 1178-1190
-
Pregnancy in women with dilated cardiomyopathy genetic variants
Revista Espanola de Cardiologia
-
Prevalence and characteristics of transthyretin amyloid cardiomyopathy in hypertrophic cardiomyopathy
ESC Heart Failure
-
Prevalence of transthyretin cardiac amyloidosis in patients with heart failure with preserved ejection fraction: the PRACTICA study
Revista Espanola de Cardiologia
-
REALM-DCM: A Phase 3, Multinational, Randomized, Placebo-Controlled Trial of ARRY-371797 in Patients With Symptomatic LMNARelated Dilated Cardiomyopathy
Circulation: Heart Failure, Vol. 17, Núm. 7, pp. e011548
-
Rare Genetic Variants in Young Adults Requiring Pacemaker Implantation
JACC: Clinical Electrophysiology, Vol. 10, Núm. 10, pp. 2250-2260
-
Role of TBX20 Truncating Variants in Dilated Cardiomyopathy and Left Ventricular Noncompaction
Circulation: Genomic and Precision Medicine, Vol. 17, Núm. 2, pp. E004404
-
Standard-of-Care Medication Withdrawal in Patients With Obstructive Hypertrophic Cardiomyopathy Receiving Aficamten in FOREST-HCM
Journal of the American College of Cardiology, Vol. 84, Núm. 19, pp. 1839-1849
2023
-
2023 ESC Guidelines for the management of cardiomyopathies
European heart journal, Vol. 44, Núm. 37, pp. 3503-3626
-
Association between common cardiovascular risk factors and clinical phenotype in patients with hypertrophic cardiomyopathy from the European Society of Cardiology (ESC) EurObservational Research Programme (EORP) Cardiomyopathy/Myocarditis registry
European Heart Journal - Quality of Care and Clinical Outcomes, Vol. 9, Núm. 1, pp. 42-53
-
Development and Validation of a Prediction Model and Score for Transthyretin Cardiac Amyloidosis Diagnosis: T-Amylo
JACC: Cardiovascular Imaging, Vol. 16, Núm. 12, pp. 1567-1580
-
Emery-Dreifuss muscular dystrophy Type 1 is associated with a high risk of malignant ventricular arrhythmias and end-stage heart failure
European Heart Journal, Vol. 44, Núm. 48, pp. 5064-5073